TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Income Statement
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
14.18 USD
-0.1 (-0.7%)
14.18 USD
0 (0%)
| TTM (2025-9-30) | 2025 (2025-3-31) | 2024 (2024-3-31) | 2023 (2023-3-31) | 2022 (2022-3-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 4417.00B | 4581.55B | 4263.76B | 4027.48B | 3569.01B | |||
| Minority Interest Expense | -211.00M | -215.00M | -130.00M | -21.00M | -107.00M | |||
| Cost Of Goods | 1563.69B | 1580.22B | 1426.68B | 1244.07B | 1106.85B | |||
| Gross Profit | 2853.32B | 3001.33B | 2837.08B | 2783.41B | 2462.16B | |||
| Operating Expenses | 2479.74B | 2464.30B | 2406.30B | 2232.51B | 1916.67B | |||
| Research and Development | 691.57B | 730.23B | 729.92B | 633.33B | 526.09B | |||
| Selling, General, and Administrative Expenses | 1075.89B | 1104.77B | 1053.82B | 997.31B | 886.36B | |||
| Operating Income | 373.58B | 537.03B | 430.79B | 550.89B | 545.49B | |||
| Interest Income/Expense | -147.66B | -181.97B | -196.48B | -158.20B | -142.63B | |||
| Other Income/Expense | N/A | 0.00 | 1.00M | N/A | 1.00M | |||
| Non Recurring Items | -128.01B | -179.97B | -181.51B | -17.60B | -100.29B | |||
| Income Before Taxes | 97.91B | 175.08B | 52.79B | 375.09B | 302.57B | |||
| Income Tax | 64.63B | 66.94B | -91.41B | 58.05B | 72.41B | |||
| Net Income | 33.08B | 107.93B | 144.07B | 317.02B | 230.06B | |||
| EBITDA | 1116.92B | 1298.43B | 1158.79B | 1215.30B | 1128.64B | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 10.80 | 34.13 | 45.98 | 100.83 | 72.84 | |||
| Non GAAP EPS | 10.70 | 34.13 | 45.98 | 102.07 | 73.53 | |||
| Statistics | ||||||||
| Gross Profit Margin | 64.60% | 65.51% | 66.54% | 69.11% | 68.99% | |||
| Profit Margin | 0.75% | 2.36% | 3.38% | 7.87% | 6.45% | |||
| Operating Profit Margin | 8.46% | 11.72% | 10.10% | 13.68% | 15.28% | |||
All data in JPY